These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28340323)

  • 1. A key to the backdoor into the castle: The clinical ramifications of immunoediting driven by antigenic competition.
    Hanna MG; Howard JD
    Hum Vaccin Immunother; 2017 Jul; 13(7):1579-1585. PubMed ID: 28340323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunoediting: A process driven by metabolic competition as a predator-prey-shared resource type model.
    Kareva I; Berezovskaya F
    J Theor Biol; 2015 Sep; 380():463-72. PubMed ID: 26116366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer immunotherapy: how low-level ionizing radiation can play a key role.
    Janiak MK; Wincenciak M; Cheda A; Nowosielska EM; Calabrese EJ
    Cancer Immunol Immunother; 2017 Jul; 66(7):819-832. PubMed ID: 28361232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The three Es of cancer immunoediting.
    Dunn GP; Old LJ; Schreiber RD
    Annu Rev Immunol; 2004; 22():329-60. PubMed ID: 15032581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From mice to humans: developments in cancer immunoediting.
    Teng MW; Galon J; Fridman WH; Smyth MJ
    J Clin Invest; 2015 Sep; 125(9):3338-46. PubMed ID: 26241053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reverse immunoediting: When immunity is edited by antigen.
    Merlo A; Dalla Santa S; Dolcetti R; Zanovello P; Rosato A
    Immunol Lett; 2016 Jul; 175():16-20. PubMed ID: 27131431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early stages of 1,2-dimethylhydrazine-induced colon carcinogenesis suppress immune-regulated ion transport of mouse distal colon.
    Broaddus RR; Wargovich MJ; Castro GA
    Cancer Res; 1994 Nov; 54(22):5930-6. PubMed ID: 7954425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
    Adachi K; Tamada K
    Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunologic consequences of laparoscopy in oncology.
    Carter JJ; Whelan RL
    Surg Oncol Clin N Am; 2001 Jul; 10(3):655-77. PubMed ID: 11685934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunosurveillance and immunoediting by natural killer cells.
    Gross E; Sunwoo JB; Bui JD
    Cancer J; 2013; 19(6):483-9. PubMed ID: 24270347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer vaccines: harnessing the potential of anti-tumor immunity.
    Suckow MA
    Vet J; 2013 Oct; 198(1):28-33. PubMed ID: 23850019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cancer and immunosuppression : experimental aspects].
    Maral J; Florentin I; Soubrane C; Maral R
    Bull Cancer; 1983; 70(5):351-71. PubMed ID: 6230125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
    Curigliano G; Criscitiello C; Esposito A; Fumagalli L; Gelao L; Locatelli M; Minchella I; Goldhirsch A
    Breast; 2013 Aug; 22 Suppl 2():S96-9. PubMed ID: 24074802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.
    Smyth MJ; Dunn GP; Schreiber RD
    Adv Immunol; 2006; 90():1-50. PubMed ID: 16730260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human × human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy.
    Hugwil AV
    Med Hypotheses; 2013 Sep; 81(3):489-95. PubMed ID: 23856243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunoediting and "spontaneous" tumor regression.
    Sengupta N; MacFie TS; MacDonald TT; Pennington D; Silver AR
    Pathol Res Pract; 2010 Jan; 206(1):1-8. PubMed ID: 19945228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer immunoediting from immune surveillance to immune escape.
    Kim R; Emi M; Tanabe K
    Immunology; 2007 May; 121(1):1-14. PubMed ID: 17386080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle-based immunotherapy for cancer.
    Shao K; Singha S; Clemente-Casares X; Tsai S; Yang Y; Santamaria P
    ACS Nano; 2015 Jan; 9(1):16-30. PubMed ID: 25469470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
    Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
    Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.